NZ716687A - Il-18 binding molecules - Google Patents

Il-18 binding molecules

Info

Publication number
NZ716687A
NZ716687A NZ716687A NZ71668713A NZ716687A NZ 716687 A NZ716687 A NZ 716687A NZ 716687 A NZ716687 A NZ 716687A NZ 71668713 A NZ71668713 A NZ 71668713A NZ 716687 A NZ716687 A NZ 716687A
Authority
NZ
New Zealand
Prior art keywords
binding molecules
bind
bound
complex
inflammatory diseases
Prior art date
Application number
NZ716687A
Inventor
Christian Carsten Silvester Kunz
Michael Otto Bardroff
Barbara Brannetti
Emma Michelle Campbell
Beate Diefenbach-Streiber
Adina Eberth
Sylwia Marshall
Jean-Michel Rene Rondeau
Jean-Marc Alfred Schlaeppi
Heeke Gino Anselmus Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ716687A publication Critical patent/NZ716687A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
NZ716687A 2012-09-07 2013-09-05 Il-18 binding molecules NZ716687A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261697981P 2012-09-07 2012-09-07
NZ70482513 2013-09-05

Publications (1)

Publication Number Publication Date
NZ716687A true NZ716687A (en) 2017-03-31

Family

ID=58397952

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ716687A NZ716687A (en) 2012-09-07 2013-09-05 Il-18 binding molecules

Country Status (1)

Country Link
NZ (1) NZ716687A (en)

Similar Documents

Publication Publication Date Title
MX2020007022A (en) Il-18 binding molecules.
CL2014003110A1 (en) Anti-fcrn antibody; sequences that encode it; vector; host cell; production process; pharmaceutical composition comprising it; use for the treatment of autoimmune disease; and assay to test the ability of an antibody to block human fcrn activity.
MX2010010387A (en) Bcr-complex-specific antibodies and methods of using same.
MX2010009190A (en) HUMANIZED ANTI-C5aR ANTIBODIES.
EA201492149A1 (en) ST2 Antigen Binding Proteins
EA201291067A1 (en) HUMANIZED ANTIGENSORATING PROTEINS FOR MYOSTATIN
MX356800B (en) Humanized tau antibody.
EA201492137A1 (en) ANTIBODIES TO CD33 AND THEIR APPLICATION IN CANCER TREATMENT
MX2014014218A (en) Il-6 binding molecules.
SG10201808738WA (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
EA201790438A1 (en) ANTIGEN-BINDING PROTEINS THAT CONNECT WITH CXCR5
UA106529C2 (en) Humanized antibodies to cxcr4 for cancer treatment
EP3085786A3 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
MX2015005757A (en) Her3 antigen binding proteins binding to the beta-hairpin of her3.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
MX366046B (en) Binding molecules that bind human complement factor c2 and uses thereof.
WO2013103899A3 (en) Phosphorylation of histones and uses thereof
NZ716687A (en) Il-18 binding molecules
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
ES2481517A2 (en) Method for the diagnosis of parkinson's disease in early stages (Machine-translation by Google Translate, not legally binding)
TH167242B (en) Molecular adhesion IL-18
TH167242A (en) Molecular adhesion IL-18
NZ768582A (en) Antibodies and uses thereof to detect folate receptor 1
TN2011000150A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2018 BY CPA GLOBAL

Effective date: 20170817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2019 BY CPA GLOBAL

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2020 BY CPA GLOBAL

Effective date: 20190822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2021 BY CPA GLOBAL

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2022 BY CPA GLOBAL

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2023 BY CPA GLOBAL

Effective date: 20220818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2024 BY CPA GLOBAL

Effective date: 20230817